Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
about
Cyclo-oxygenase (COX) inhibitors for threatened miscarriageEvidence-based use of indomethacin and ibuprofen in the neonatal intensive care unitPiroxicam-β-cyclodextrin: a GI safer piroxicamLipid mediators and allergic diseasesPost-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomalleiAre cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future AntidepressantsPosttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNACXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factorDifferential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro studyEffects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infectionVariable platelet response to aspirin in patients with ischemic strokeThe electrophile responsive proteome: integrating proteomics and lipidomics with cellular functionIL-17 mediated inflammation promotes tumor growth and progression in the skinImplications of altered glutathione metabolism in aspirin-induced oxidative stress and mitochondrial dysfunction in HepG2 cellsTL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRILY294002 inhibits glucocorticoid-induced COX-2 gene expression in cardiomyocytes through a phosphatidylinositol 3 kinase-independent mechanismChronic inflammatory diseases are stimulated by current lifestyle: how diet, stress levels and medication prevent our body from recoveringProstaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells.Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells.Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice.Formation of 8-nitroguanine, a nitrative DNA lesion, in inflammation-related carcinogenesis and its significance.The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgeryThe functional -765G→C polymorphism of the COX-2 gene may reduce the risk of developing crohn's diseaseThrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouseProstaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studiesLipid mediators and human leukemic blasts.Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials.Uteroglobin inhibits prostaglandin F2alpha receptor-mediated expression of genes critical for the production of pro-inflammatory lipid mediators.Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis.Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer.A review of the emerging profile of the anti-inflammatory drug oxaprozin.Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis.Sphingosine 1-phosphate mediates hyperalgesia via a neutrophil-dependent mechanism.Translational systems biology of inflammation: potential applications to personalized medicine.Myocardial Infarction and Its Association with the Use of Nonselective NSAIDs: A Nested Case-Control and Time-to-Event Analysis.Prostaglandin E2 promotes MYCN non-amplified neuroblastoma cell survival via β-catenin stabilizationIntraplantar-injected ceramide in rats induces hyperalgesia through an NF-κB- and p38 kinase-dependent cyclooxygenase 2/prostaglandin E2 pathway.
P2860
Q24194009-C2BBAD48-5369-4D47-9DF8-65BE5AD268A8Q24604121-15D0837B-D376-4920-A9CA-6133FF9ECDD5Q27023475-43775076-3882-4D7C-ACE5-545AD260A424Q27023936-22BECEA2-C03E-44BA-B1A3-D7E97F05517DQ27305217-237C759E-1144-4885-96AA-F6FACD91C6AAQ27324133-5BD14FE3-8C48-4D9A-8204-6A63357DBC56Q28082891-265B251C-85BD-4421-8AA4-FAC5B0643DB7Q28114829-66FB6631-2D2C-4C56-B5F9-EA14AC5B92E9Q28116204-3355AAAC-1FCD-412C-8D30-5D752E66B9A2Q28193949-714BD380-ABD5-45FD-8CDB-C47CD45830B2Q28196516-31F23025-7633-4C65-AB86-EF7265D28F56Q28211221-B1006091-9B06-4038-BB09-94AEC119AB0BQ28388959-D3415D4E-0B36-4DC3-809A-D9E4276DB11AQ28480915-FCF276C2-563C-464B-8A6A-48D50BE3D1D5Q28483005-C878E8D4-452C-4A71-9EF5-894D36C4FD33Q28540575-A16FD362-692D-4A12-9821-F3FED37A38F5Q28580875-D369BFFF-429B-455D-9A31-1638F53D7A38Q30415505-73A5CBF1-17F9-47F2-BD9C-C5B75980B300Q30430640-E090DF0F-D14C-4ABB-8820-DD9CD8B34A02Q30436782-1E3D1224-E5A7-43A7-917F-D50961BAB796Q33640054-F5D1A6D9-E676-477D-8859-2493AA591BCDQ33665928-4B6B2C35-5383-42F0-9174-DD8607ECCBA9Q33680126-AB6E4B05-A038-4CE4-995B-7489D9CC3900Q33760727-D62AC7F7-D47B-4E81-9841-DFCBA915D415Q33918377-339D486E-86A1-44D7-91FD-0B25B8B78371Q34079832-EEE05664-D73D-4DC9-AA4C-42AB97B349E8Q34161193-63306CE0-44D4-4024-8377-4515FB42B28DQ34189041-D747A87B-27A2-42A0-88D9-5480E3274585Q34290335-9E989DEC-E721-48AE-B19A-EFB56505A658Q34439275-3D897CD6-CB9D-4711-96C2-25A28B2C7F6FQ34449825-CCD76A3D-8A93-4C78-B27B-6F5F04E50825Q34502422-29D3866C-581F-4F90-95CA-7DF8BCA03BE7Q34521937-2A94F20E-DB7D-4A38-88C4-98770A303124Q34558203-8BF1F51F-B2DD-4D2B-A525-1878E863F333Q34571335-DD49AFF6-8070-47D8-8AD3-775C31ED09C5Q34571684-D6075B82-7DFB-4A9A-8869-E05C6AB99AA8Q34585279-01385188-62A4-4D2E-98DA-67025421A2CEQ34589334-29B143B8-D77B-49B7-9B3C-4B612240F28AQ34885515-7C1B50B3-B548-485F-AF62-FBFAA002336BQ35105360-68F64749-3B47-41D3-BBA4-99BC25942265
P2860
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
@ast
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
@en
type
label
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
@ast
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
@en
prefLabel
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
@ast
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
@en
P356
P1433
P1476
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
@en
P2093
Jane A Mitchell
P304
P356
10.1096/FJ.03-0645REV
P407
P577
2004-05-01T00:00:00Z